Compare CRI & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRI | MNMD |
|---|---|---|
| Founded | 1865 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 960.2M |
| IPO Year | 2003 | N/A |
| Metric | CRI | MNMD |
|---|---|---|
| Price | $31.77 | $12.98 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $28.80 | $26.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $2,832,687,000.00 | N/A |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | $0.14 | N/A |
| P/E Ratio | $13.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.38 | $4.70 |
| 52 Week High | $56.89 | $14.43 |
| Indicator | CRI | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 59.34 |
| Support Level | $31.80 | $12.00 |
| Resistance Level | $33.38 | $13.15 |
| Average True Range (ATR) | 1.25 | 0.67 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 18.73 | 73.94 |
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).